Neurocrine biosciences appoints dr. ingrid delaet as chief regulatory officer

San diego , sept. 29, 2022 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) announced today that dr. ingrid delaet will join the company's executive management team as chief regulatory officer effective october 1, leading the regulatory affairs, quality assurance, medical writing, and program management teams.

NBIX Ratings Summary

NBIX Quant Ranking